NasdaqCM:CORT

Stock Analysis Report

Executive Summary

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Corcept Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.3%

CORT

-0.2%

US Pharmaceuticals

1.0%

US Market


1 Year Return

12.5%

CORT

-6.0%

US Pharmaceuticals

6.7%

US Market

Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned -6% over the past year.

Return vs Market: CORT exceeded the US Market which returned 6.7% over the past year.


Share holder returns

CORTIndustryMarket
7 Day0.3%-0.2%1.0%
30 Day5.7%-0.5%-1.8%
90 Day31.5%-2.6%-1.8%
1 Year12.5%12.5%-3.7%-6.0%9.1%6.7%
3 Year120.3%120.3%17.4%9.1%46.0%36.6%
5 Year370.0%370.0%28.0%14.5%66.9%48.6%

Price Volatility Vs. Market

How volatile is Corcept Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Corcept Therapeutics undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: CORT ($14.1) is trading below our estimate of fair value ($58.08)

Significantly Undervalued: CORT is trading below fair value by more than 20%.


Price Based on Earnings

PE vs Industry: CORT is poor value based on its PE Ratio (20.7x) compared to the Pharmaceuticals industry average (16.7x).

PE vs Market: CORT is poor value based on its PE Ratio (20.7x) compared to the US market (17.5x).


Price Based on Expected Growth

Low PEG Ratio: CORT is poor value based on its PEG Ratio (1.6x)


Price Based on Value of Assets

PB vs Industry: CORT is overvalued based on its PB Ratio (5.4x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is Corcept Therapeutics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

13.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: CORT's forecast earnings growth (13.2% per year) is above the savings rate (2.7%).

Earnings vs Market: CORT's earnings (13.2% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: CORT's earnings are forecast to grow, but not significantly.

Revenue vs Market: CORT's revenue (9.9% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CORT's revenue (9.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if CORT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Corcept Therapeutics performed over the past 5 years?

69.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CORT has become profitable over the past 5 years, growing earnings by 69.9% per year.

Accelerating Growth: CORT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CORT had negative earnings growth (-47.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (24.3%).


Return on Equity

High ROE: CORT's Return on Equity (26.2%) is considered high.


Return on Assets

ROA vs Industry: CORT has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: CORT has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Corcept Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CORT's short term assets ($232.7M) exceeds its short term liabilities ($30.4M)

Long Term Liabilities: CORT's short term assets ($232.7M) exceeds its long term liabilities ($245.0K)


Debt to Equity History and Analysis

Debt Level: CORT is debt free.

Reducing Debt: CORT has no debt compared to 5 years ago when its debt to equity ratio was 1030.2%.

Debt Coverage: CORT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CORT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: CORT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CORT's debt is covered by short term assets.


Next Steps

Dividend

What is Corcept Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.3%forecastin3Years0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate CORT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CORT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CORT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CORT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CORT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Corcept Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.5yrs

Average management tenure


CEO

Joseph Belanoff (62yo)

20.8yrs

Tenure

US$6,314,617

Compensation

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h ...


CEO Compensation Analysis

Compensation vs. Market: Joseph's total compensation ($USD6.31M) is about average for companies of similar size in the US market ($USD4.08M).

Compensation vs Earnings: Joseph's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

3.5yrs

Average Tenure

57yo

Average Age

Experienced Management: CORT's management team is considered experienced (3.5 years average tenure).


Board Age and Tenure

20.8yrs

Average Tenure

65yo

Average Age

Experienced Board: CORT's board of directors are seasoned and experienced ( 20.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$1,138,71014 Feb 19
George Baker
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares100,000
Max PriceUS$11.39
BuyUS$1,272,55026 Nov 18
George Baker
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares100,000
Max PriceUS$12.73
BuyUS$2,589,23014 Nov 18
George Baker
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares200,000
Max PriceUS$13.00

Ownership Breakdown


Management Team

  • Joseph Belanoff (62yo)

    Co-Founder

    • Tenure: 20.8yrs
    • Compensation: US$6.31m
  • Hazel Hunt

    Senior Vice President of Research

    • Tenure: 2.6yrs
  • Chris James

    Director of Investor Relations

    • Tenure: 0yrs
  • Charlie Robb (56yo)

    CFO & Secretary

    • Tenure: 8.1yrs
    • Compensation: US$2.85m
  • Don Laferle

    Senior Vice President

    • Tenure: 0yrs
  • Sean Maduck (42yo)

    Senior Vice President of Commercial

    • Tenure: 3.5yrs
    • Compensation: US$2.81m
  • Andreas Grauer (58yo)

    Chief Medical Officer

    • Tenure: 0.6yrs

Board Members

  • Len Baker (76yo)

    Independent Director

    • Tenure: 20.8yrs
    • Compensation: US$267.89k
  • David Mahoney (65yo)

    Independent Director

    • Tenure: 15.3yrs
    • Compensation: US$272.89k
  • Charles Nemeroff (69yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jim Wilson (75yo)

    Independent Chairman

    • Tenure: 20.8yrs
    • Compensation: US$758.67k
  • Dan Swisher (56yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$280.26k
  • Joseph Belanoff (62yo)

    Co-Founder

    • Tenure: 20.8yrs
    • Compensation: US$6.31m
  • Florian Holsboer

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Bruce McEwen

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Ned Kalin

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • K. Ranga Krishnan (63yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Corcept Therapeutics Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Corcept Therapeutics Incorporated
  • Ticker: CORT
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.603b
  • Shares outstanding: 113.69m
  • Website: https://www.corcept.com

Number of Employees


Location

  • Corcept Therapeutics Incorporated
  • 149 Commonwealth Drive
  • Menlo Park
  • California
  • 94025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CORTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2004
HTDDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2004
0I3QLSE (London Stock Exchange)YesCommon StockGBUSDApr 2004

Biography

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym ( ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:37
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)